Defining Subjective Cognitive Decline

Subjective cognitive decline (SCD) can be one of the earliest noticeable signs of Alzheimer's disease, yet SCD is not yet fully understood. To help us understand more, Dr. Frank Jessen, an expert in the field, joins the podcast to discuss how SCD is defined, classified, and evaluated in both clinical and research settings.

Guest: Frank Jessen, MD, professor of psychiatry and psychotherapy, director, department of psychiatry, University of Cologne, clinical board member, Clinical Alzheimer's Research, German Center of Neurodegenerative Disease (DZNE), chair, European Alzheimer’s Disease Consortium (EADC), founder and past chairman, ISTARRT Professional Interest Area on SCD, SCD-initiative (SCD-I), founder, chair, German Memory Clinic Network (DNG), advisory board, German Alzheimer Association, Hirnliga

Show Notes

Read Dr. Jessen's study, “The characterisation of subjective cognitive decline,” on the National Library of Medicine website.

Learn more about Dr. Jessen at his profile on the DZNE website.

Connect with us

Find transcripts and more at our website.

Email Dementia Matters: dementiamatters@medicine.wisc.edu

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.

Learn about Dr. Chin’s book, When Memory Fades: What to Expect at Every Stage, from Early Signs to Full Support for Alzheimer's and Dementia.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(246)

Examining Environmental Factors' Effects on Cognition

New research is looking at the effects of environmental factors on the brain as we age. Dr. Kathryn Conlon joins the podcast to discuss how factors like air pollution and lead exposure can affect cogn...

22 Sep 42min

Blood Tests and Brain Scans and Biomarkers, Oh My! How Biomarkers are Changing Alzheimer’s Disease Clinical Trials

In recent years, the U.S. Food and Drug Administration (FDA) has approved new biomarker tools for Alzheimer’s disease, including blood tests and tracers for brain scans. How are these tools used in re...

8 Sep 45min

New Alzheimer’s Association Special Report Breaks Down How Americans Understand and Support their Brain Health

In recent years, public interest in brain health has increased. So how are Americans understanding brain health information and incorporating it into their own lives? This year, the Alzheimer’s Associ...

25 Aug 37min

Reflecting on 25 Years of the Wisconsin Registry for Alzheimer’s Prevention

Twenty-five years ago, a single participant enrolled in what would become the Wisconsin Registry for Alzheimer's Prevention (WRAP), now one of the largest and longest-running studies of Alzheimer's ri...

12 Aug 35min

How Dementia Caregiving Affects the Spousal Caregiver

Caring for those with dementia represents a major public health challenge, with caregivers, especially spouses, providing long-term, largely unpaid care. With caregiving stress linked to a decline in ...

28 Juli 39min

Managing the Medicine Cabinet: How Prescriptions Impact Cognition and Brain Health as We Age

Prescription medications, over-the-counter drugs and supplements are incredibly common among older adults, yet many of these routine treatments can unexpectedly impact cognitive function and brain hea...

14 Juli 35min

Taking a Deep Dive into Subjective Cognitive Decline

Dr. Jessen returns to the podcast to take a deeper dive into subjective cognitive decline (SCD). Aiming to cover everything relating to SCD, Dr. Jessen shares insights in prognosis, risk factors and h...

7 Juli 17min